Avanteca Partners
Overview
A privately held asset management company based in Basel, Switzerland, that invests in early-stage life science companies. The firm focuses on innovations in new chemical or biological entities (NCEs or NBEs), vaccines, and digital health applications with a direct impact on disease. It acts as both a financial provider and a strategic partner, offering operational experience to its portfolio companies.
Portfolio Companies
4
Website
avanteca.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Oncobit | Apr 2021 | Seed | Co-investor |
| Onena Medicines | Oct 2023 | Series A | Lead |
| Bearmind | Jul 2023 | Seed | Co-investor |
| Nanoligent | Oct 2025 | Series A | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Avanteca Partners based?
Avanteca Partners is headquartered in Basel, Basel-Stadt, Switzerland.
When was Avanteca Partners founded?
Founding year information for Avanteca Partners is not publicly available.
How many portfolio companies does Avanteca Partners have?
Avanteca Partners has 4 portfolio companies in Caplight's dataset.
What are some companies in Avanteca Partners's portfolio?
Portfolio companies visible on Caplight include Oncobit, Onena Medicines, Bearmind, Nanoligent.
What was Avanteca Partners's most recent investment shown here?
Avanteca Partners's most recent investment in this portfolio sample was in Nanoligent in 2025.
What sectors does Avanteca Partners focus on?
Avanteca Partners focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure.
What company stages does Avanteca Partners focus on?
Avanteca Partners typically invests at the Early stage.